Newsbenzinga
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
· Published
Article summary
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
An excerpt from the original article.
Comments —
Loading comments…